These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21372619)

  • 1. Proteomic approach to the study of statin pleiotropy in kidney transplant patients.
    Pérez V; Navarro-Muñoz M; Mas S; Bayés B; Pastor MC; Martínez-Cáceres E; Lauzurica R; Egido J; Romero R
    Pharmacology; 2011; 87(3-4):161-8. PubMed ID: 21372619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low doses of atorvastatin on the urinary peptide profile of kidney transplant patients.
    Pérez V; Navarro-Muñoz M; Bayés B; Lauzurica R; Pastor MC; Troya M; Bonet J; Ibernón M; Navarro M; Serra A; Núñez A; Romero R
    Transplant Proc; 2009; 41(6):2111-4. PubMed ID: 19715847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.
    Höglund K; Wiklund O; Vanderstichele H; Eikenberg O; Vanmechelen E; Blennow K
    Arch Neurol; 2004 Mar; 61(3):333-7. PubMed ID: 15023808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
    Joukhadar C; Klein N; Prinz M; Schrolnberger C; Vukovich T; Wolzt M; Schmetterer L; Dorner GT
    Thromb Haemost; 2001 Jan; 85(1):47-51. PubMed ID: 11204586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia.
    Ercan E; Tengiz I; Altuglu I; Sekuri C; Aliyev E; Ercan HE; Akin M
    Kardiol Pol; 2004 May; 60(5):454-8. PubMed ID: 15247960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study.
    Panichi V; Manca-Rizza G; Paoletti S; Taccola D; Consani C; Sbragia G; Mantuano E; Marchetti V; Carpi A; Barsotti G
    Biomed Pharmacother; 2006 Jun; 60(5):249-52. PubMed ID: 16740374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
    Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
    Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    Leibovitz E; Harats D; Gavish D
    Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
    Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
    Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
    Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
    Chiang CK; Yang SY; Peng YS; Hsu SP; Pai MF; Huang JW; Hung KY; Wu KD
    Am J Nephrol; 2009; 29(5):392-7. PubMed ID: 18974640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.